CSF2 and neoplasm: A commercially available OV product, T-VEC, is genetically engineered to express GM-CSF and enhance the recruitment of antigen-presenting cells (APCs) to the immunosuppressive tumor microenvironment, which leads to the recruitment of other cytokines and enhances anti-tumor activity [65,66].